PACIRA BIOSCIENCES, INC. Costs and Expenses
PACIRA BIOSCIENCES, INC. (PCRX) reported Costs and Expenses of $188.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. costs and expenses for the quarter ending 2026-06-30 was $188.13M, a 9.00% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs and expenses for the quarter ending 2026-03-31 was $170.47M, a 2.12% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs and expenses for the quarter ending 2025-12-31 was $194.53M, a 19.68% increase year-over-year.
- PACIRA BIOSCIENCES, INC. costs and expenses for the quarter ending 2025-09-30 was $173.15M, a 43.80% decline year-over-year.
- PACIRA BIOSCIENCES, INC. costs and expenses for fiscal 2025 was $707.22M, a 8.67% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. costs and expenses for fiscal 2024 was $774.34M, a 31.85% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. costs and expenses for fiscal 2023 was $587.30M, a 3.21% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. costs and expenses for fiscal 2022 was $606.80M, a 34.36% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $188.13M 10-Q · filed 2026-08-04 | $358.61M 10-Q · filed 2026-08-04 | $553.14M derived: sum of 3 quarters · filed 2026-08-04 | $726.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $170.47M 10-Q · filed 2026-04-30 | $365.01M derived: sum of 2 quarters · filed 2026-04-30 | $538.16M derived: sum of 3 quarters · filed 2026-04-30 | $710.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $194.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $367.69M derived: sum of 2 quarters · filed 2026-02-26 | $540.29M derived: sum of 3 quarters · filed 2026-08-04 | $707.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $173.15M 10-Q · filed 2025-11-06 | $345.75M derived: sum of 2 quarters · filed 2026-08-04 | $512.69M 10-Q · filed 2025-11-06 | $675.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $172.60M 10-Q · filed 2026-08-04 | $339.53M 10-Q · filed 2026-08-04 | $502.08M derived: sum of 3 quarters · filed 2026-08-04 | $810.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $166.93M 10-Q · filed 2026-04-30 | $329.48M derived: sum of 2 quarters · filed 2026-04-30 | $637.58M derived: sum of 3 quarters · filed 2026-04-30 | $787.37M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $162.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $470.65M derived: sum of 2 quarters · filed 2026-02-26 | $620.43M derived: sum of 3 quarters · filed 2026-02-26 | $774.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | $308.10M 10-Q · filed 2025-11-06 | $457.88M derived: sum of 2 quarters · filed 2025-11-06 | $611.79M 10-Q · filed 2025-11-06 | $759.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $149.78M 10-Q · filed 2025-08-05 | $303.69M 10-Q · filed 2025-08-05 | $451.76M derived: sum of 3 quarters · filed 2026-02-26 | $597.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $153.91M 10-Q · filed 2025-05-08 | $301.98M derived: sum of 2 quarters · filed 2026-02-26 | $448.19M derived: sum of 3 quarters · filed 2026-02-26 | $577.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $148.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $294.28M derived: sum of 2 quarters · filed 2026-02-26 | $423.87M derived: sum of 3 quarters · filed 2026-02-26 | $587.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $146.21M 10-Q · filed 2024-11-06 | $275.80M derived: sum of 2 quarters · filed 2024-11-06 | $439.23M 10-Q · filed 2024-11-06 | $621.08M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $129.59M 10-Q · filed 2024-07-30 | $293.02M 10-Q · filed 2024-07-30 | $474.87M derived: sum of 3 quarters · filed 2024-07-30 | $621.05M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $163.43M 10-Q · filed 2024-05-07 | $345.28M derived: sum of 2 quarters · filed 2024-05-07 | $491.46M derived: sum of 3 quarters · filed 2024-05-07 | $629.63M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $181.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $328.02M derived: sum of 2 quarters · filed 2024-02-29 | $466.20M derived: sum of 3 quarters · filed 2024-02-29 | $606.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $146.18M 10-Q · filed 2023-11-02 | $284.35M derived: sum of 2 quarters · filed 2023-11-02 | $424.95M 10-Q · filed 2023-11-02 | $579.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $138.18M 10-Q · filed 2023-08-02 | $278.77M 10-Q · filed 2023-08-02 | $433.76M derived: sum of 3 quarters · filed 2024-02-29 | $530.05M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $140.60M 10-Q · filed 2023-05-03 | $295.58M derived: sum of 2 quarters · filed 2024-02-29 | $391.87M derived: sum of 3 quarters · filed 2024-02-29 | $492.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $154.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $251.27M derived: sum of 2 quarters · filed 2024-02-29 | $352.02M derived: sum of 3 quarters · filed 2024-02-29 | $451.61M 10-K · filed 2024-02-29 |
| 2021-09-30 | $96.29M 10-Q · filed 2022-11-03 | $197.04M derived: sum of 2 quarters · filed 2022-11-03 | $296.63M 10-Q · filed 2022-11-03 | $408.82M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $100.75M 10-Q · filed 2022-08-03 | $200.34M 10-Q · filed 2022-08-03 | $312.53M derived: sum of 3 quarters · filed 2022-08-03 | $412.39M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $99.59M 10-Q · filed 2022-05-04 | $211.78M derived: sum of 2 quarters · filed 2022-05-04 | $311.64M derived: sum of 3 quarters · filed 2022-05-04 | $394.30M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $112.19M 10-K · filed 2021-03-01 | $212.06M derived: sum of 2 quarters · filed 2021-11-03 | $294.71M derived: sum of 3 quarters · filed 2021-11-03 | $383.30M 10-K · filed 2023-02-28 |
| 2020-09-30 | $99.86M 10-Q · filed 2021-11-03 | $182.52M derived: sum of 2 quarters · filed 2021-11-03 | $271.11M 10-Q · filed 2021-11-03 | $391.82M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $82.65M 10-Q · filed 2021-08-03 | $171.24M 10-Q · filed 2021-08-03 | $291.95M derived: sum of 3 quarters · filed 2021-08-03 | $394.23M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $88.59M 10-Q · filed 2021-05-04 | $209.30M derived: sum of 2 quarters · filed 2021-05-04 | $311.57M derived: sum of 3 quarters · filed 2021-05-04 | $408.90M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $120.71M 10-K · filed 2021-03-01 | $222.98M derived: sum of 2 quarters · filed 2021-03-01 | $320.31M derived: sum of 3 quarters · filed 2021-03-01 | $410.55M 10-K · filed 2022-02-28 |
| 2019-09-30 | $102.27M 10-K · filed 2021-03-01 | $199.60M derived: sum of 2 quarters · filed 2021-03-01 | $289.84M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $97.33M 10-K · filed 2021-03-01 | $187.56M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $90.23M 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $321.36M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |